Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-28

Avid Bioservices (CDMO)

CEO Nicholas Green was paid $4,475,343 in fiscal year 2024, ↓ down 30.7% from fiscal year 2023, the 36th percentile of its disclosed peer group (SEC filing 0001683168-24-006081 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$4,475,343 ↓
Nicholas Green total, FY2024
36th
CEO pay percentile vs peers
35:1
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Nicholas Green (President and Chief Executive Officer), FY2024 total compensation $4,475,343 (base salary $650,000) [exec_comp, SEC accession 0001683168-24-006081, filed 2024-08-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Nicholas Green$650,000$0$3,776,336$0$0$0$49,007$4,475,343
President and Chief Executive Officer
Daniel Hart445,0000944,07500052,1571,441,232
Chief Financial Officer
Mark Ziebell425,0000557,00100052,1571,034,158
Vice President, General Counsel and Corporate Secretary
Matthew Kwietniak362,0000566,43900047,433975,872
Chief Commercial Officer
Richard Richieri375,0000472,02700036,907883,934
Chief Operations Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Nicholas Green$4,475,343$6,461,784$6,181,824↓ −1,986,441
Daniel Hart1,441,2321,936,8982,067,208↓ −495,666
Mark Ziebell1,034,1581,377,3991,291,708↓ −343,241
Matthew Kwietniak975,8721,283,884—↓ −308,012
Richard Richieri883,9341,109,387—↓ −225,453

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Avid Bioservices's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CDMO reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CDMO
2 companies name CDMO as a compensation peer

Each company listed discloses CDMO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDMO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Catherine J. Mackey, Ph.DIndependent Director$245,185
Esther M. Alegria, Ph.DIndependent Director$240,185
Gregory P. SargenIndependent Director$245,185
Jeanne A. ThomaIndependent Director$245,185
Joseph Carleone, Ph.DChair of the Board$275,185
Richard B. HancockIndependent Director$240,185
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Nicholas Stewart GreenDirector2024-12-31A1,755$6$10,621CommonForm 4 ↗
Richard RichieriChief Operations Officer2024-12-31A1,30367,886CommonForm 4 ↗
Richard RichieriChief Operations Officer2024-12-31A1,755610,621CommonForm 4 ↗
Daniel HartChief Financial Officer2024-12-31A1,755610,621CommonForm 4 ↗
Dividend-equivalent accruals2025-01-09—2,976——1 insider, 7 accrual rows
Richard RichieriChief Operations Officer2025-01-09D2,99500Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09A464——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09A5,507——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-10D2,2831228,241CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-10D200122,474CommonForm 4 ↗
Richard B. HancockDirector2025-01-27D20,12800CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D11,755——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D54,455——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D2,000——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D104,000——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D455,512——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D7,794——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D32,100——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D98,120——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D37,746——CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D159,375——CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D102,730——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D124,191——CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D113,878——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D2,938——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D30,635——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D50,796——CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D4,817——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D1,430——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D107,137——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D59,212——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D8,785——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D49,535——CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D36,368——CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D45,611——CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D17,679——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D55,310——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D14,286——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D66,799——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D1,650——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D8,376——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D130,324——CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D308,486——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D11,623——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D112,735——CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D1,733——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D48,498——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D77,454——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D881——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D58,018——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D108,579——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D51,413——Derivative, Class A CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D19,403——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D92,461——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D71,120——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D54,760——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D7,014——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D34,271——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D56,250——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D21,429——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D43,379——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 86 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Nicholas Stewart GreenDirector2024-12-31A1,755$6$10,621CommonForm 4 ↗
Richard RichieriChief Operations Officer2024-12-31A1,30367,886CommonForm 4 ↗
Richard RichieriChief Operations Officer2024-12-31A1,755610,621CommonForm 4 ↗
Daniel HartChief Financial Officer2024-12-31A1,755610,621CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D20900Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D2,99500Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D1,06000Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D94600Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09A464——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D13200Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D8300Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D4000Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09D50600Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-09A5,507——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-10D2,2831228,241CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-01-10D200122,474CommonForm 4 ↗
Richard B. HancockDirector2025-01-27D20,12800CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D11,755——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D54,455——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D2,000——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D104,000——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D455,512——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D7,794——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D32,100——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D98,120——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D37,746——CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D159,375——CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D102,730——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D124,191——CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D113,878——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D2,938——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D30,635——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D50,796——CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D4,817——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D1,430——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D107,137——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D59,212——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D8,785——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D49,535——CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D36,368——CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D45,611——CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D17,679——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D55,310——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D14,286——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D66,799——CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D1,650——Derivative, Class A CommonForm 4 ↗
Esther M. AlegriaDirector2025-02-05D8,376——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D130,324——CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D308,486——Derivative, Class A CommonForm 4 ↗
Nicholas Stewart GreenDirector2025-02-05D75,000——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D11,623——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D112,735——CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D10,030——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D1,733——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Gregory P. SargenDirector2025-02-05D19,600——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D48,498——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D77,454——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D881——Derivative, Class A CommonForm 4 ↗
Matthew KwietniakChief Commercial Officer2025-02-05D58,018——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D108,579——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D51,413——Derivative, Class A CommonForm 4 ↗
Jeanne A. ThomaDirector2025-02-05D19,403——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D92,461——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D71,120——Derivative, Class A CommonForm 4 ↗
Daniel HartChief Financial Officer2025-02-05D54,760——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D7,014——Derivative, Class A CommonForm 4 ↗
Richard B. HancockDirector2025-02-05D34,271——Derivative, Class A CommonForm 4 ↗
Richard RichieriChief Operations Officer2025-02-05D56,250——Derivative, Class A CommonForm 4 ↗
Mark ZiebellV. P., General Counsel2025-02-05D21,429——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D8,147——Derivative, Class A CommonForm 4 ↗
Joseph CarleoneDirector2025-02-05D19,675——Derivative, Class A CommonForm 4 ↗
Catherine J. MacKeyDirector2025-02-05D43,379——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Richard RichieriPSU2023-07-098,47825,433—33,911$236,013
Matthew KwietniakPSU2023-07-0910,17330,520—40,693283,223
Nicholas GreenPSU2023-07-0967,822203,467—271,2891,888,171
Matthew KwietniakRSU2023-07-09——20,346—283,216
Mark ZiebellPSU2023-07-0910,00430,011—40,015278,504
Daniel HartPSU2023-07-0916,95650,867—67,822472,034
Mark ZiebellRSU2023-07-09——20,007—278,497
Daniel HartRSU2023-07-09——33,911—472,041
Richard RichieriRSU2023-07-09——16,955—236,014
Nicholas GreenRSU2023-07-09——135,644—1,888,165
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Richard Richieri$236,014$236,013$050.0%
Matthew Kwietniak283,216283,223050.0%
Nicholas Green1,888,1651,888,171050.0%
Mark Ziebell278,497278,504050.0%
Daniel Hart472,041472,034050.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark ZiebellPSU20,007—$40,014
Matthew KwietniakPSU30,520—40,693
Richard RichieriPSU16,955—33,908
Richard RichieriRSU8,478—16,955
Nicholas GreenPSU135,644—271,290
Mark ZiebellPSU30,011—40,015
Matthew KwietniakRSU162,563—191,250
Nicholas GreenRSU208,038—244,750
Daniel HartPSU50,867—67,822
Daniel HartRSU143,438—168,750
Richard RichieriRSU138,465—162,900
Nicholas GreenPSU203,467—271,289
Mark ZiebellRSU10,004—20,008
Matthew KwietniakPSU20,346—40,694
Matthew KwietniakRSU10,173—20,347
Daniel HartRSU16,956—33,911
Daniel HartPSU33,911—67,820
Richard RichieriPSU25,433—33,911
Nicholas GreenRSU67,822—135,645
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation philosophy is to provide compensation that will attract, motivate, retain and reward high-performing talent in our industry and foster a pay-for-performance philosophy by tying a significant portion of pay to financial performance as well as other goals that support the creation of sustainable long-term stockholder value.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantAnderson Pay Advisors, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
07

CEO pay ratio

Ratio (CEO : median employee)35 : 1
CEO total compensation$4,475,343
Median employee compensation$126,552
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Joseph Carleone, Ph.DIndependent · Board Chair · CDMO Business and Operations Leadership · Finance Capital Markets · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance$120,000$155,185$0——$275,185
Catherine J. Mackey, Ph.DIndependent · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance90,000155,1850——245,185
Gregory P. SargenIndependent · Audit (Chair)90,000155,1850——245,185
Jeanne A. ThomaIndependent · CDMO Business and Operations Leadership · Risk Oversight · Human Resources and Executive Compensation · Corporate Governance90,000155,1850——245,185
Esther M. Alegria, Ph.DIndependent · Audit85,000155,1850——240,185
Richard B. HancockIndependent · Audit85,000155,1850——240,185
Nicholas S. GreenEmployee director · CDMO Business and Operations Leadership · Finance Capital Markets—————0
09

Board fee structure and ownership guideline

Annual cash retainer$55,000
Annual equity retainer$140,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 20,000
Stock ownership guideline$165,000
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$560,000
Equity awards (grant-date value)$931,110
All other compensation$0
Total cost of the board$1,491,110

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Avid Bioservices names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Avid Bioservices.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Twist Bioscience Corporation2025Emily Leproust$720,000$11,998,134$0$932,918$13,781,570
2ANI Pharmaceuticals, Inc.2025Nikhil Lalwani837,4097,848,71101,572,50010,278,620
3Standard BioTools Inc.2025Michael Egholm680,2565,337,8831,671,3631,120,0008,823,502
4CareDx, Inc.2025John Hanna693,2695,622,6380852,5157,179,699
5Emergent BioSolutions Inc.2025Joseph Papa1,037,3851,638,5001,191,5001,446,6405,321,147
6Quanterix Corporation2025Masoud Toloue670,9501,170,0002,729,998674,1725,250,745
7Rigel Pharmaceuticals, Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
8Avid Bioservices2024Nicholas Green650,0003,776,336004,475,343
9Pacific Biosciences of California, Inc.2025Christian Henry748,2501,151,0131,696,278714,3054,309,846
10Codexis, Inc.2025Alison Moore524,732255,9941,065,223463,1252,323,279
11Lifecore Biomedical, Inc.2025Paul Josephs550,000274,996——1,115,305
12Harvard Bioscience, Inc.2025John Duke203,077598,90000905,208
—Codiak BioSciences, Inc.——————not in coverage universe
—Sangamo Therapeutics, Inc.——————not in coverage universe
—ChromaDex Corporation——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Avid Bioservices0%RSU 50 · PSU 50NoAnderson Pay Advisors, LLC
ANI Pharmaceuticals, Inc.185%RSU 75 · PSU 25Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences IndexPearl Meyer & Partners, LLC
CareDx, Inc.122%RSU 70 · PSU 30NoAlpine Rewards
ChromaDex Corporationnot disclosednot disclosednot disclosednot disclosed
Codexis, Inc.95%not disclosednot disclosedPearl Meyer
Codiak BioSciences, Inc.not disclosednot disclosednot disclosednot disclosed
Emergent BioSolutions Inc.107%Options 50 · PSU 50NoWTW
Harvard Bioscience, Inc.not disclosedRSU 50 · PRSU 50Yes — Relative Total Shareholder Return (TSR)Frederic W. Cook & Co., Inc.
Lifecore Biomedical, Inc.not disclosednot disclosednot disclosedFrederic W. Cook & Co.
Pacific Biosciences of California, Inc.95%not disclosednot disclosedAon Human Capital Solutions
Quanterix Corporation95%Options 70 · RSU 30not disclosedPayGov
Rigel Pharmaceuticals, Inc.124%Options 75 · RSU 25NoPearl Meyer
Sangamo Therapeutics, Inc.not disclosednot disclosednot disclosedAon
Standard BioTools Inc.160%not disclosednot disclosedPearl Meyer
Twist Bioscience Corporation129.6%PSU 50 · RSU 50Nonot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Avid Bioservices in fiscal 2024?
As disclosed, Nicholas Green (President and Chief Executive Officer) was the highest-paid executive at Avid Bioservices in fiscal 2024, with total compensation of $4,475,343.
How does Avid Bioservices's chief executive pay compare to its disclosed peer group?
As disclosed, Nicholas Green's total compensation ranked at the 36th percentile of Avid Bioservices's disclosed peer group.
What is Avid Bioservices's CEO-to-median employee pay ratio?
As disclosed, Avid Bioservices's CEO-to-median employee pay ratio was 35:1.
How much does Avid Bioservices spend in total on board compensation for fiscal 2024?
As disclosed, Avid Bioservices reported total board compensation of $1,491,110 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Nicholas GreenDEF 14A2024-08-280001683168-24-006081Section “Executive Compensation”. As printed: 4,475,343. Filing ↗machine: r1 · c8 · span 442595–442604
2Section 01, Daniel HartDEF 14A2024-08-280001683168-24-006081Section “Executive Compensation”. As printed: 1,441,232. Filing ↗machine: r4 · c8 · span 445197–445206
3Section 01, Mark ZiebellDEF 14A2024-08-280001683168-24-006081Section “Executive Compensation”. As printed: 1,034,158. Filing ↗machine: r13 · c8 · span 452945–452954
4Section 01, Matthew KwietniakDEF 14A2024-08-280001683168-24-006081Section “Executive Compensation”. As printed: 975,872. Filing ↗machine: r10 · c8 · span 450396–450403
5Section 01, Richard RichieriDEF 14A2024-08-280001683168-24-006081Section “Executive Compensation”. As printed: 883,934. Filing ↗machine: r7 · c8 · span 447798–447805
6Section 03, Richard Richieri PSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 480223–480230
7Section 03, Matthew Kwietniak PSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
8Section 03, Nicholas Green PSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
9Section 03, Matthew Kwietniak RSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 486971–486978
10Section 03, Mark Ziebell PSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
11Section 03, Daniel Hart PSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
12Section 03, Mark Ziebell RSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 492089–492096
13Section 03, Daniel Hart RSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
14Section 03, Richard Richieri RSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
15Section 03, Nicholas Green RSUDEF 14A1900-01-010001683168-24-006081Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 471825–471834
16Section 07, pay ratioDEF 14A2024-08-280001683168-24-006081Section “CEO Pay Ratio”. As printed: 35 : 1. Filing ↗
17Section 08, Joseph Carleone, Ph.DDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 275,185. Filing ↗machine: span 253992–253999
18Section 08, Catherine J. Mackey, Ph.DDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 245,185. Filing ↗machine: span 255799–255806
19Section 08, Gregory P. SargenDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 245,185. Filing ↗machine: span 256703–256710
20Section 08, Jeanne A. ThomaDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 245,185. Filing ↗machine: span 257594–257601
21Section 08, Esther M. Alegria, Ph.DDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 240,185. Filing ↗machine: span 253082–253089
22Section 08, Richard B. HancockDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 240,185. Filing ↗machine: span 254897–254904
23Section 08, Nicholas S. GreenDEF 14A2024-08-280001683168-24-006081Section “Director Compensation”. As printed: 0. Filing ↗
24Section 02, Nicholas Stewart Green 2024-12-31Form 42025-01-020001683168-25-000033Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Richard Richieri 2024-12-31Form 42025-01-020001683168-25-000035Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Richard Richieri 2024-12-31Form 42025-01-020001683168-25-000035Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Daniel Hart 2024-12-31Form 42025-01-020001683168-25-000034Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Richard Richieri 2025-01-09Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Richard Richieri 2025-01-10Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Richard Richieri 2025-01-10Form 42025-01-130001683168-25-000297Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Richard B. Hancock 2025-01-27Form 42025-01-290001683168-25-000585Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Matthew Kwietniak 2025-02-05Form 42025-02-070001683168-25-000859Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Catherine J. MacKey 2025-02-05Form 42025-02-070001683168-25-000860Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Esther M. Alegria 2025-02-05Form 42025-02-070001683168-25-000854Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Esther M. Alegria 2025-02-05Form 42025-02-070001683168-25-000854Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Matthew Kwietniak 2025-02-05Form 42025-02-070001683168-25-000859Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Catherine J. MacKey 2025-02-05Form 42025-02-070001683168-25-000860Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Jeanne A. Thoma 2025-02-05Form 42025-02-070001683168-25-000863Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Jeanne A. Thoma 2025-02-05Form 42025-02-070001683168-25-000863Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Esther M. Alegria 2025-02-05Form 42025-02-070001683168-25-000854Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Nicholas Stewart Green 2025-02-05Form 42025-02-070001683168-25-000856Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Catherine J. MacKey 2025-02-05Form 42025-02-070001683168-25-000860Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Catherine J. MacKey 2025-02-05Form 42025-02-070001683168-25-000860Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Gregory P. Sargen 2025-02-05Form 42025-02-070001683168-25-000862Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Matthew Kwietniak 2025-02-05Form 42025-02-070001683168-25-000859Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Matthew Kwietniak 2025-02-05Form 42025-02-070001683168-25-000859Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Matthew Kwietniak 2025-02-05Form 42025-02-070001683168-25-000859Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Jeanne A. Thoma 2025-02-05Form 42025-02-070001683168-25-000863Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Daniel Hart 2025-02-05Form 42025-02-070001683168-25-000858Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Richard B. Hancock 2025-02-05Form 42025-02-070001683168-25-000857Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Richard Richieri 2025-02-05Form 42025-02-070001683168-25-000861Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Mark Ziebell 2025-02-05Form 42025-02-070001683168-25-000864Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Joseph Carleone 2025-02-05Form 42025-02-070001683168-25-000855Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Catherine J. MacKey 2025-02-05Form 42025-02-070001683168-25-000860Insider equity transaction reported since the proxy statement. Filing ↗
110Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
111Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
112Section 09b board cost (computed)Computed——Cash 560,000 + equity 931,110 + all other 0 = 1,491,110, summed across the director compensation table rows.machine: formula: Σ = 1,491,110
113Twist Bioscience Corporation, Section 10b CEO totalDEF 14A2026-01-060001581280-26-000006CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961
114ANI Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-090001023024-26-000039CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154
115Standard BioTools Inc., Section 10b CEO totalDEF 14A2026-04-270001140361-26-017100CEO total compensation as printed in Standard BioTools Inc.'s own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266
116CareDx, Inc., Section 10b CEO totalDEF 14A2026-04-270001217234-26-000028CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661
117Emergent BioSolutions Inc., Section 10b CEO totalDEF 14A2026-03-200001367644-26-000033CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. Filing ↗machine: t155 · r3 · c15 · span 906918–906927
118Quanterix Corporation, Section 10b CEO totalDEF 14A2026-04-240001104659-26-048166CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085
119Rigel Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-030001034842-26-000023CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068
120Avid Bioservices (subject), Section 10b CEO totalDEF 14A2024-08-280001683168-24-006081CEO total compensation as printed in Avid Bioservices's own proxy. As printed: 4,475,343. Filing ↗machine: r1 · c8 · span 442595–442604
121Pacific Biosciences of California, Inc., Section 10b CEO totalDEF 14A2026-04-230001299130-26-000064CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983
122Codexis, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186994CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937
123Lifecore Biomedical, Inc., Section 10b CEO totalDEF 14A2026-04-240001005286-26-000012CEO total compensation as printed in Lifecore Biomedical, Inc.'s own proxy. As printed: 1,115,305. Filing ↗
124Harvard Bioscience, Inc., Section 10b CEO totalDEF 14A2026-04-210001171843-26-002617CEO total compensation as printed in Harvard Bioscience, Inc.'s own proxy. As printed: 905,208. Filing ↗machine: r2 · c25 · span 341394–341401
125Section 10a, ANI Pharmaceuticals, Inc. reciprocityDEF 14A—0001023024-26-000039ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
126Section 10a, CareDx, Inc. reciprocityDEF 14A—0001217234-26-000028CareDx, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
127Section 10a, Codexis, Inc. reciprocityDEF 14A—0001193125-25-093503Codexis, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
128Section 10a, Rigel Pharmaceuticals, Inc. reciprocityDEF 14A—0001034842-26-000023Rigel Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
129Section 10a, Emergent BioSolutions Inc. reciprocityDEF 14A—0001367644-26-000033Emergent BioSolutions Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
130Section 10a, Standard BioTools Inc. reciprocityDEF 14A—0001140361-26-017100Standard BioTools Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
131Section 10a, Lifecore Biomedical, Inc. reciprocityDEF 14A—0001005286-26-000012Lifecore Biomedical, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
132Section 10a, Pacific Biosciences of California, Inc. reciprocityDEF 14A—0001299130-26-000064Pacific Biosciences of California, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
133Section 10a, Quanterix Corporation reciprocityDEF 14A—0001104659-26-048166Quanterix Corporation's most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗
134Section 10a, Harvard Bioscience, Inc. reciprocityDEF 14A—0001171843-25-002341Harvard Bioscience, Inc.'s most recent proxy was read; its disclosed peer group does not include Avid Bioservices. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.